ArticleAmerican journal of translational research2026
Short-term clinical remission rates and adverse reactions of rituximab compared to cyclosporine in patients with refractory membranous nephropathy (MN).
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare short-term remission rates, adverse events, and laboratory trends between rituximab (RTX) and cyclosporine A (CsA) in refractory membranous nephropathy (MN), and to identify independent predictors of 12-month remission.
methodsThis retrospective cohort study enrolled 165 patients with refractory MN (RTX: 85, CsA: 80). Primary outcome was clinical remission (complete or partial) at 6 and 12 months. Cumulative remission was assessed by Kaplan-Meier analysis. Multivariable logistic regression identified factors associated with 12-month remission. Adverse events were recorded throughout follow-up.
resultsBaseline characteristics were largely balanced, although the RTX group had lower proteinuria (6.47±1.84 vs. 7.14±1.70 g/24 h, P=0.016) and eGFR (66.71±9.80 vs. 74.82±9.50 mL/min/1.73 m
conclusionsOver 12 months, CsA induced higher remission rates than RTX in refractory MN, albeit with more adverse events and a measurable effect on renal function. RTX offered a better safety profile but slower onset of action. Baseline proteinuria and eGFR independently predicted remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.